On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
Biosimilars of filgrastim (original brand name: Gran), a recombinant human granulocyte colony stimulating factor (G-CSF), were rolled out on May 31 by two pairs of companies, creating Japan’s first battlefield for biosimilars. On top of its solid domestic business foundation,…
To read the full story
BUSINESS
- Japan Pharma Market Put at 13 Trillion Yen in FY2031, Growth to Slow: IQVIA
November 11, 2026
- Eisai Nets Double-Digit Sales, Profit Growth on Core Products, Weak Yen
November 11, 2026
- Kyorin Targets 10 Billion Yen-Plus Assets in Licensing Push
November 11, 2026
- FRONTEO, TagCyx Deepen AI Drug Discovery Tie-Up
November 11, 2026
- Nitrosamines Found in Sertraline, Telmisartan Generics; Shipments to Continue
November 11, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…